KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Advanced/ Metastatic Non–Small-Cell Lung Cancer (NSCLC) Harboring KRAS G12C Mutation
Jänne, P.A., Rybkin, I.I., Spira, A.I., Riely, G.J., Papadopoulos, K.P., Sabari, J.K., Johnson, M.L., Heist, R.S., Bazhenova, L., Barve, M., Pacheco, J.M., Leal, T.A., Velastegui, K., Cornelius, C., Olson, P., Christensen, J.G., Kheoh, T., Chao, R.C., Ou, S.H.I.
Published in European journal of cancer (1990) (01.10.2020)
Published in European journal of cancer (1990) (01.10.2020)
Get full text
Journal Article
1133P Additional practice-informing adverse event patterns and management in the KRYSTAL-1 phase II study of adagrasib (MRTX849) in patients with KRASG12C-mutated NSCLC
Zhang, J., Leventakos, K., Leal, T.A., Pennell, N., Barve, M., Paulson, A.S., Bazhenova, L., Johnson, M.L., Chao, R.C., Velastegui, K., Qian, C., Bleker, W., Spira, A.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
LBA6 KRYSTAL-1: Adagrasib (MRTX849) as monotherapy or combined with cetuximab (Cetux) in patients (Pts) with colorectal cancer (CRC) harboring a KRASG12C mutation
Weiss, J., Yaeger, R.D., Johnson, M.L., Spira, A., Klempner, S.J., Barve, M.A., Christensen, J.G., Chi, A., Der-Torossian, H., Velastegui, K., Kheoh, T., Ou, S-H.I.
Published in Annals of oncology (01.09.2021)
Published in Annals of oncology (01.09.2021)
Get full text
Journal Article
MA06.04 KRYSTAL-1: Two-Year Follow-Up of Adagrasib (MRTX849) Monotherapy in Patients with Advanced/Metastatic KRASG12C-Mutated NSCLC
Gadgeel, S., Jänne, P.A., Spira, A.I., Ou, S.-H.I., Heist, R.S., Pacheco, J.M., Johnson, M.L., Sabari, J.K., Leventakos, K., Mason, J.A., Velastegui, K., Yan, X., Chao, R., Riely, G.J.
Published in Journal of thoracic oncology (01.11.2023)
Published in Journal of thoracic oncology (01.11.2023)
Get full text
Journal Article
LBA24 KRYSTAL-1: Updated efficacy and safety of adagrasib (MRTX849) with or without cetuximab in patients with advanced colorectal cancer (CRC) harboring a KRASG12C mutation
Klempner, S.J., Weiss, J., Pelster, M., Spira, A., Barve, M., Ou, S-H.I., Leal, T.A., Bekaii-Saab, T., Christensen, J.G., Kheoh, T., Velastegui, K., Torossian, H. Der, Yaeger, R.
Published in Annals of oncology (01.09.2022)
Published in Annals of oncology (01.09.2022)
Get full text
Journal Article
8MO Adagrasib (MRTX849) in patients with advanced/metastatic KRAS G12C-mutated non-small cell lung cancer (NSCLC): Preliminary analysis of mutation allele frequency
Jänne, P.A., Spira, A., Riely, G.J., Gadgeel, S., Heist, R., Ou, S-H.I., Johnson, M.L., Sabari, J., Velastegui, K., Christensen, J.G., Yang, W., Anderes, K., Chao, R., Paweletz, C.
Published in Journal of thoracic oncology (01.04.2023)
Published in Journal of thoracic oncology (01.04.2023)
Get full text
Journal Article
KRYSTAL-1: Activity and Safety of Adagrasib (MRTX849) in Patients with Colorectal Cancer (CRC) and Other Solid Tumors Harboring a KRAS G12C Mutation
Johnson, M.L., Ou, S.H.I., Barve, M., Rybkin, I.I., Papadopoulos, K.P., Leal, T.A., Velastegui, K., Christensen, J.G., Kheoh, T., Chao, R.C., Weiss, J.
Published in European journal of cancer (1990) (01.10.2020)
Published in European journal of cancer (1990) (01.10.2020)
Get full text
Journal Article
PS02.08 Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy
Leal, T.A., Horn, L., Velastegui, K., Christensen, J., Chen, I., Spira, A.
Published in Journal of thoracic oncology (01.11.2017)
Published in Journal of thoracic oncology (01.11.2017)
Get full text
Journal Article
PS02.08 Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitor Therapy: Topic: Medical Oncology
Leal, T.A., Horn, L., Velastegui, K., Christensen, J., Chen, I., Spira, A.
Published in Journal of thoracic oncology (01.11.2017)
Published in Journal of thoracic oncology (01.11.2017)
Get full text
Journal Article
99O_PR KRYSTAL-1: Activity and preliminary pharmacodynamic (PD) analysis of adagrasib (MRTX849) in patients (Pts) with advanced non–small cell lung cancer (NSCLC) harboring KRASG12C mutation
Riely, G.J., Ou, S-H.I., Rybkin, I., Spira, A., Papadopoulos, K., Sabari, J.K., Johnson, M., Heist, R.S., Bazhenova, L., Barve, M., Pacheco, J.M., Velastegui, K., Cilliers, C., Olson, P., Christensen, J.G., Kheoh, T., Chao, R.C., Jänne, P.A.
Published in Journal of thoracic oncology (01.04.2021)
Published in Journal of thoracic oncology (01.04.2021)
Get full text
Journal Article
MA 02.01 Evidence of Clinical Activity of Sitravatinib in Combination with Nivolumab in NSCLC Patients Progressing on Prior Checkpoint Inhibitors
Leal, T., Campbell, T., Mapes, A., Schneider, K., Staab, M.J., Velastegui, K., Christensen, J., Chen, I., Traynor, A.
Published in Journal of thoracic oncology (01.11.2017)
Published in Journal of thoracic oncology (01.11.2017)
Get full text
Journal Article